ReviewJournal of pregnancy2026
Pregnancy in Autosomal Dominant Polycystic Kidney Disease: Maternal and Fetal Considerations: A Narrative Review.
Review in Journal of pregnancy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pregnancy in Autosomal Dominant Polycystic Kidney Disease: Maternal and Fetal Considerations: A Narrative Review.Journal of pregnancy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsAutosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and an important cause of kidney failure among individuals of reproductive age. Although its management in nonpregnant adults is well established, the implications of ADPKD during pregnancy remain less clearly defined. The aim of this review is to summarize maternal and fetal risks and provide practical management considerations for pregnancy in individuals with ADPKD.
methodsA narrative review of the literature was conducted using PubMed/MEDLINE and relevant clinical practice guidelines, focusing on pregnancy-related outcomes and management considerations in individuals with ADPKD.
resultsPregnant individuals with ADPKD face higher risks of chronic hypertension, proteinuria, hypertensive disorders of pregnancy, and preterm delivery compared with the general population. Strict blood pressure targets used outside of pregnancy may compromise uteroplacental perfusion, highlighting the importance of pregnancy-appropriate goals and safe antihypertensive choices. Renin-angiotensin system inhibitors and disease-modifying therapies such as tolvaptan are contraindicated due to fetal safety concerns. Monitoring strategies include regular assessment of blood pressure, kidney function, and fetal growth. Emerging imaging data suggest that pregnancy may accelerate kidney and liver cyst growth, although long-term consequences remain uncertain. Additional strategies such as low-dose aspirin, biochemical markers for preeclampsia risk assessment, and renal ultrasound for baseline evaluation may be considered.
conclusionPregnancy in individuals with ADPKD requires individualized, multidisciplinary care with careful attention to blood pressure control, medication safety, and maternal and fetal monitoring. Further research is needed to better understand long-term outcomes and optimize management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.